Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1:193-201. doi: 10.1590/s0074-02762011000900024.
The lack of immunogenicity of most malaria antigens and the complex immune responses required for achieving protective immunity against this infectious disease have traditionally hampered the development of an efficient human malaria vaccine. The current boom in development of recombinant viral vectors and their use in prime-boost protocols that result in enhanced immune outcomes have increased the number of malaria vaccine candidates that access pre-clinical and clinical trials. In the frontline, adenoviruses and poxviruses seem to be giving the best immunization results in experimental animals and their mutual combination, or their combination with recombinant proteins (formulated in adjuvants and given in sequence or being given as protein/virus admixtures), has been shown to reach unprecedented levels of anti-malaria immunity that predictably will be somehow reproduced in the human setting. However, all this optimism was previously seen in the malaria vaccine development field without many real applicable results to date. We describe here the current state-of-the-art in the field of recombinant adenovirus research for malaria vaccine development, in particular referring to their use in combination with other immunogens in heterologous prime-boost protocols, while trying to simultaneously show our contributions and point of view on this subject.
大多数疟疾抗原缺乏免疫原性，以及实现针对这种传染病的保护性免疫所需的复杂免疫反应，这传统上阻碍了有效人类疟疾疫苗的开发。目前，重组病毒载体的发展蓬勃发展，并在引发增强免疫效果的初免-加强方案中得到应用，这增加了进入临床前和临床试验的疟疾疫苗候选者数量。在前沿领域，腺病毒和痘病毒似乎在实验动物中提供了最佳的免疫效果，并且它们的相互组合，或者与重组蛋白（在佐剂中配制并按顺序给予或作为蛋白/病毒混合物给予）的组合，已经达到了前所未有的抗疟免疫水平，可以预计在人类环境中以某种方式再现。然而，在此之前，在疟疾疫苗开发领域已经看到了所有这些乐观情绪，但迄今为止并没有很多实际适用的结果。我们在这里描述了重组腺病毒研究在疟疾疫苗开发领域的最新进展，特别是在异源初免-加强方案中与其他免疫原结合使用的情况，同时试图展示我们在这个主题上的贡献和观点。
